Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Huan, Taoa; 1 | Tran, Trana; 1 | Zheng, Jiamina | Sapkota, Shraddhab | MacDonald, Stuart W.c | Camicioli, Richardb; d | Dixon, Roger A.b; e; * | Li, Lianga; *
Affiliations: [a] Department of Chemistry, University of Alberta, Edmonton, Canada | [b] Neuroscience and Mental Health Institute, University of Alberta, Edmonton, Canada | [c] Department of Psychology, University of Victoria, British Columbia, Canada | [d] Department of Medicine (Neurology), University of Alberta, Edmonton, Canada | [e] Department of Psychology, University of Alberta, Edmonton, Canada
Correspondence: [*] Correspondence to: Liang Li, Department of Chemistry, Chemistry Centre W3-39C, University of Alberta, Edmonton, Alberta, T6G 2G2, Canada. Tel.: +1 780 492 3250; E-mail: [email protected] and Roger A. Dixon, Department of Psychology, P-217 Biological Sciences Building, University of Alberta, Edmonton, Alberta, T6G 2E9, Canada. Tel.: +1 780 492 7602; E-mail: [email protected].
Note: [1] These authors contributed equally to this work.
Abstract: Using a non-invasive biofluid (saliva), we apply a powerful metabolomics workflow for unbiased biomarker discovery in Alzheimer’s disease (AD). We profile and differentiate Cognitively Normal (CN), Mild Cognitive Impairment (MCI), and AD groups. The workflow involves differential chemical isotope labeling liquid chromatography mass spectrometry using dansylation derivatization for in-depth profiling of the amine/phenol submetabolome. The total sample (N = 109) was divided in to the Discovery Phase (DP) (n = 82; 35 CN, 25 MCI, 22 AD) and a provisional Validation Phase (VP) (n = 27; 10 CN, 10 MCI, 7 AD). In DP we detected 6,230 metabolites. Pairwise analyses confirmed biomarkers for AD versus CN (63), AD versus MCI (47), and MCI versus CN (2). We then determined the top discriminating biomarkers and diagnostic panels. A 3-metabolite panel distinguished AD from CN and MCI (DP and VP: Area Under the Curve [AUC] = 1.000). The MCI and CN groups were best discriminated with a 2-metabolite panel (DP: AUC = 0.779; VP: AUC = 0.889). In addition, using positively confirmed metabolites, we were able to distinguish AD from CN and MCI with good diagnostic performance (AUC > 0.8). Saliva is a promising biofluid for both unbiased and targeted AD biomarker discovery and mechanism detection. Given its wide availability and convenient accessibility, saliva is a biofluid that can promote diversification of global AD biomarker research.
Keywords: Alzheimer’s disease, biomarkers, liquid chromatography mass spectrometry, metabolomics, saliva, Victoria Longitudinal Study
DOI: 10.3233/JAD-180711
Journal: Journal of Alzheimer's Disease, vol. 65, no. 4, pp. 1401-1416, 2018
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]